CPT

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated

Retrieved on: 
星期四, 五月 9, 2024
Project, FDA, Sale, Mayo Clinic, Genomics, Health, Nebula Genomics, Research, Insurance, Collection, Water, Consultant, Genetic testing, Development, Public expenditure, Automation, DNA, SNP, Esophageal cancer, Data, Omicron, Algorithm, Three Months, Patient, CPT, Acquisition, Prophase, Food, Diagnosis, Immunity, Nebula, HRSA, Absorption, COVID-19, Engineering, Medical device

Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
  • Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
  • Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
  • Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 五月 9, 2024
DAS, AMD, Boehringer Ingelheim, Research, Johnson & Johnson, Conference, Webcast, Conference call, Patient, M&A, CPT, Eye, Pharming, Conditional sentence, Data analysis, MBA, Drug delivery, Clinical trial, Biotechnology, ARVO, Visual acuity, Pharmaceutical industry

ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
  • License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023.
  • Other expense for the first quarter of 2024 was $1.5 million, compared to $0 for the first quarter of 2023.
  • Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.

Retrieved on: 
星期四, 五月 9, 2024
Project, FDA, Sale, Mayo Clinic, Genomics, Health, Nebula Genomics, Research, Insurance, Collection, Water, Consultant, Genetic testing, Development, Public expenditure, Automation, DNA, SNP, Esophageal cancer, Data, Omicron, Algorithm, Three Months, Patient, CPT, Acquisition, Prophase, Food, Diagnosis, Immunity, Nebula, HRSA, Absorption, COVID-19, Engineering

Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
  • Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
  • Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
  • Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.

Introducing the Composability Framework V1.1

Retrieved on: 
星期三, 四月 24, 2024
DTC, Capability, Abbreviation, AI, XR, Responsibility, OMG, Augmented reality, VR, Extended reality, CPT, Virtual reality, ESG, GM, Digital twin, Ethics, Data management, Organization, Architecture, Information technology

The latest iteration reflects our commitment to continuous improvement, driven by our community's valuable insights and active participation.

Key Points: 
  • The latest iteration reflects our commitment to continuous improvement, driven by our community's valuable insights and active participation.
  • "Serving as the key part of the Composability Framework, the CPT facilitates greater flexibility and innovation, ensuring that digital twin system development focuses on interoperability,  scalability, design reuse, and aligned with the evolving needs of businesses."
  • This encapsulates ethics, ESG criteria, AI explainability, and fairness, underscoring the need for responsible and trustworthy digital twin operations.
  • Capability Mapping - To ease the transition from the initial framework, we provide a detailed mapping from the 1.0 to 1.1 capabilities.

2024 DTA Summit Agenda is LIVE!!

Retrieved on: 
星期二, 四月 16, 2024
PFS, Single-frequency network, Policy, PDT, Digital, Medicare Sustainable Growth Rate, Therapy, CPT, Access, Medicare, H.R, Organization, DTA, Pharmaceutical industry

Arlington, VA, April 16, 2024 (GLOBE NEWSWIRE) -- Digital Therapeutics Alliance is excited to announce the launch of the highly anticipated agenda for the upcoming 2024 DTA Summit.

Key Points: 
  • Arlington, VA, April 16, 2024 (GLOBE NEWSWIRE) -- Digital Therapeutics Alliance is excited to announce the launch of the highly anticipated agenda for the upcoming 2024 DTA Summit.
  • The DTA Summit aims to bring together industry leaders, visionaries, and practitioners to explore the latest advancements and strategies shaping the future of digital transformation.
  • As organizations worldwide navigate unprecedented challenges and opportunities in the digital health landscape, the DTA Summit serves as a crucial platform for knowledge exchange, collaboration, and inspiration.
  • New in 2024, the DTA Summit will host a live Start-Up Pitch Competition.

Dexios Sees Success in Capturing Charges on the Front-end That Would Cause Denials on the Backend

Retrieved on: 
星期二, 四月 30, 2024
Mobile, Wireless, Technology, Medical Devices, Hospitals, Other Technology, Radiology, General Health, Health, Data Management, Artificial Intelligence, Hospital, AI, Insurance, Partnership, Collection, ICD-10, RCM, Patient, CPT, Medicine, Medicare, MIPS, Maverick, Medical device

Through this collaboration, Maverick and Dexios were able to reduce coding related denials and significantly reduce medical coding queue backlogs by 71 percent.

Key Points: 
  • Through this collaboration, Maverick and Dexios were able to reduce coding related denials and significantly reduce medical coding queue backlogs by 71 percent.
  • This fostered a partnership with Maverick Medical AI in late 2023 when Dexios deployed Maverick’s platform to optimize the billing process by automating the rigorous medical coding process.
  • Reduction of 58 percent in FTE (full-time equivalent): Enables Dexios more staff flexibility, productivity, and better allocation of company resources.
  • Maverick’s Autonomous Medical Coding Platform combines extensive domain knowledge of medical coding with cutting-edge machine learning and generative AI.

Magnus Medical Announces Commercial Launch of Groundbreaking SAINT Neuromodulation System

Retrieved on: 
星期二, 四月 30, 2024
Mental Health, Health, FDA, Medical Devices, Neurology, Health Technology, General Health, SAINT, University, CMS, DSM-IV codes, MUSC, American Medical Association, Medicine, Depression, Psychiatry, Patient, CPT, NTAP, Medicare, MRI, CSO, Magnetic resonance imaging, Multimedia, MDD, TMS, Pharmaceutical industry

Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced the commercial launch of the SAINT® neuromodulation system, a groundbreaking, rapid-acting therapy for treatment-resistant major depressive disorder (MDD).

Key Points: 
  • Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced the commercial launch of the SAINT® neuromodulation system, a groundbreaking, rapid-acting therapy for treatment-resistant major depressive disorder (MDD).
  • View the full release here: https://www.businesswire.com/news/home/20240430113478/en/
    The commercially available SAINT® neuromodulation system from Magnus Medical provides a new form of individualized neurostimulation therapy for treatment-resistant major depression in adults who have failed to achieve satisfactory improvement from prior antidepressant medications.
  • The American Medical Association (AMA) issued new Category III Current Procedural Terminology (CPT) codes for targeted, accelerated iTBS for depression, encompassing the SAINT neuromodulation system, effective July 1, 2024.
  • Magnus Medical expects to have selective insurance coverage in both the hospital inpatient and outpatient setting and the physician’s office.

Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually

Retrieved on: 
星期一, 四月 29, 2024
Technology, Insurance, Health Technology, Professional Services, Cardiology, Health Insurance, Software, General Health, Health, Artificial Intelligence, Use, Radiation, University, Part, Telehealth, Diagnosis, AUC, Hospital, SPECT, Care, Cardiovascular disease, Prevalence, Molina Healthcare, Methylation, American Medical Association, Death, DNA methylation, MD, Doctor of Philosophy, CHD, Advances in Therapy, DNA, Algorithm, Patient, Moyamoya disease, CPT, PLA, Medicare, Biomarker, Intermountain Health, Associate, Medicine, VBC, Economics, CCTA, Journal, American Heart Association

PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.

Key Points: 
  • PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.
  • The model considered factors such as the number of tests performed, the cost of each test, and the impact of test results on treatment decisions.
  • The results suggest that using PrecisionCHD could lead to significant cost savings for payers, with an estimated $113.6 million saved per year for a plan with one million members.
  • These tools support targeted, data-driven decisions in CHD treatment and management, potentially revolutionizing approaches to healthcare delivery and cost management.

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024

Retrieved on: 
星期三, 四月 10, 2024
Mayo Clinic, Cancer, Genomics, Hospital, Esophageal cancer, Proteomics, Insurance, Partnership, Doctor of Philosophy, Documentation, Clinical professor, Patient, CPT, Prophase, Endoscopy, EAC, Health, GERD, Risk assessment, Medical imaging

Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.

Key Points: 
  • Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.
  • Early detection offers patients the opportunity for more favorable outcomes and a brighter, healthier future.
  • ProPhase intends to pursue and seeks to capture a significant share of a multi-billion-dollar market for EAC diagnostics.
  • Obtaining CPT codes is important for billing purposes, enabling ProPhase Labs to bill for providing the test services and receive reimbursement from insurance companies.

SAIL Fusion Announces FDA Clearance of its BowTie™ Sacroiliac Fusion System

Retrieved on: 
星期二, 四月 23, 2024
Biotechnology, Medical Supplies, Surgery, General Health, Health, FDA, Medical Devices, Hospitals, Pelvis, MIS, Rehabilitation, Surgeon, Sacroiliac joint dysfunction, TIE fighter, Orthopedic surgery, Arthrodesis, Patient, SAIL, CPT, Rigidity, Pleasure, Multimedia, 3D printing

SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced that it has received FDA clearance for its novel BowTie Sacroiliac Fusion System.

Key Points: 
  • SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced that it has received FDA clearance for its novel BowTie Sacroiliac Fusion System.
  • The system will be launched to a select group of initial surgeons in preparation for a greater expansion in the coming months.
  • “There hasn’t been meaningful differentiation in the SI fusion market for many years,” remarked David Jansen, the President & CEO of SAIL.
  • Our approach challenges the prevailing trend of lateral fixation that is more appropriate for stabilization rather than true joint fusion.